Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 8 от 240

By invitation only

Alleviant ALLAY-HF Study

Heart Failure

Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

Начало: 10.01.2023 Край: 31.07.2032 Възраст: от 40 г. Treatment

Australia, Austria, Belgium +12 Alleviant Medical, Inc. NCT05685303

By invitation only

A Spatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs

COVID-19

Conduct a study of people who use drugs (PWUD) perceptions of and access to COVID-19 vaccines as well as reasons for vaccine hesitancy/barriers

Начало: 01.01.2023 Край: 30.05.2027 Възраст: от 18 г.

United States Johns Hopkins Bloomberg School of Public Health NCT05769023

By invitation only Phase 1

Melatonin and Perinatal Outcomes in MVM-Related Fetal Growth Restriction (MIMVMFGR)

Fetal Growth Restriction (FGR)

The goal of this clinical trial is to evaluate the efficacy and safety of melatonin in the treatment of early-onset severe maternal vascular malperfusion-related fetal growth restriction (MVM-FGR), and to determine its effects on fetal growth and perinatal outcomes. The study will enroll pregnant women with singleton pregnancies diagnosed with severe MVM-FGR between 24+0 and 31+6 weeks of gestation. The main questions it aims to answer are: * Whether melatonin treatment can reduce the incidence of a composite adverse neonatal outcome, including neonatal death and severe neonatal complications. * Whether melatonin treatment can improve pregnancy and neonatal outcomes, including the interval from treatment initiation to delivery, gestational age at delivery, fetal growth trajectory throughout pregnancy (Z-score slope over time estimated using linear mixed models), neonatal birthweight, Apgar scores, neonatal complications (such as respiratory distress syndrome), maternal adverse events (such as hypertensive disorders of pregnancy), and placental pathological findings. Researchers will compare participants receiving a placebo (one capsule taken at bedtime, identical in appearance and size to melatonin) with those receiving melatonin to determine whether melatonin improves these maternal and neonatal outcomes. Participants will: • Take melatonin 10 mg orally once nightly at bedtime.

Начало: 01.01.2023 Край: 30.11.2028 Възраст: 20–43 г.

China Xinhua Hospital, Shanghai Jiao Tong University School o NCT07549295

By invitation only

Preoperative Silicone Ointment and Wound Healing

Wound Heal Scar Scar, Hypertrophic Keloid +2

Optimal scar healing is of great importance to patients, especially following surgery of the head and neck. This study evaluates the effectiveness of preoperative silicone ointment in wound healing in head and neck surgeries.

Начало: 14.11.2022 Край: 01.07.2027 Възраст: от 18 г.

United States Yale University NCT05461157

By invitation only

Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls

Motility Disorder Gastroparesis Functional Dyspepsia Cyclical Vomiting +2

This is an analytical validation observational cohort study is designed to provide evidence of: safety and reliability of Body Surface Gastric Mapping using the Gastric Alimetry System (GAS), normal reference values, and correlation of metrics with patient symptoms among healthy adults and patients diagnosed with upper abdominal motility disorders. GAS is intended to record, store, view and process gastric myoelectrical activity. This is a proprietary system consisting of multiple electrodes arranged on an array that is placed precisely over the stomach, a reader to collect the electrode measurements and a smart tablet application to track patient reported symptoms. Participants meeting inclusion and exclusion criteria will continue fasting for 30 minutes after the Gastric Alimetry System has been applied and begun measuring, eat a standard study meal within 10 minutes and remain quietly seated, reclining, for 4 hours as the GAS continues to collect data. The array is removed and the abdomen is examined for evidence of skin effects.

Начало: 01.11.2022 Край: 01.12.2028 Възраст: от 18 г.

Canada University of Calgary NCT05812339

By invitation only Phase 2/3

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis gMG

The purpose of this trial is to evaluate the long-term safety of efgartigimod IV and efgartigimod PH20 SC administered to participants with gMG in the antecedent studies, ARGX-113-2006 and ARGX-113-2207, respectively. Participants will receive efgartigimod IV or efgartigimod PH20 SC, using the dose administered in the antecedent studies. Participants who have not reached the age of 18 can remain in the study until efgartigimod becomes commercially available in the respective country or available through another continued access program for gMG. Participants who have reached the age of 18 can remain in the study for a maximum of 2 years, until efgartigimod becomes commercially available in the respective country or available through another continued access program for gMG, whichever comes first.

Начало: 18.08.2022 Край: 01.09.2029 Възраст: 2–18 г.

Belgium, Canada, France +7 argenx NCT05374590

By invitation only Phase 1/2

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

Chronic Granulomatous Disease Inflammatory Gastrointestinal Disease Inflammatory Skin Disease Inflammatory Lung Disease

Background: Chronic granulomatous disease (CGD) is a disease of the immune system, which is how the body fights germs. People with CGD get infections easily and have other health problems. Some medicines to treat CGD have a lot of side effects and do not always work. Researchers want to see if a new drug can help. Objective: To see if tofacitinib is safe to use for treating chronic CGD. Eligibility: Adults aged 18 and older with CGD who have not had success with other treatments and who are enrolled on NIH study # 93-I-0119. Design: Participants will be screened with the following: Physical exam Medical history Blood, urine, and stool tests Pregnancy test, if needed An upper gastrointestinal endoscopy and/or colonoscopy, if needed for their symptoms. Tissue samples will be collected. Skin assessment, if needed Participants will repeat some screening tests at visits. Participants will complete questionnaires about their general health and how CGD affects their daily life. Photographs will be taken of their skin, if needed. They will have lung function tests, if needed. They will have a computed tomography (CT) scan of the chest, abdomen, and pelvis, if needed. A CT scan uses X-rays to create pictures of the inside of the body. Participants will gradually reduce the amount of some CGD medicines they take. Then they will take tofacitinib as a pill twice a day or once a day for 3 months. They will keep a drug diary. They will have monthly study visits. They will have a follow-up visit about 1 month after their last study drug visit. Participation will last for about 6 months.

Начало: 12.08.2022 Край: 01.01.2027 Възраст: 18–99 г.

United States National Institute of Allergy and Infectious Diseases ( NCT05104723

By invitation only

COVID-19 Experiences in the SELF Cohort

COVID-19

Background: COVID-19 affected African Americans more than Whites. African Americans, especially women, have had higher rates of COVID-19 infections compared to Whites. They are also more likely to go to the hospital or die of this disease. Many researchers who looked into these issues lacked background data on the people they studied. SELF is a 10-year study of fibroids in African American women aged 23-35. Researchers already have a lot of data on these women. Asking how COVID-19 affected them can add context other studies lack. Objective: To describe the impact of the COVID-19 pandemic on young African American women and their families. Eligibility: Participants must be enrolled in SELF (Study of Environment, Lifestyle, and Fibroids). Design: Researchers will invite all women enrolled in SELF to participate in this natural history study. Participants will complete one questionnaire. They will answer the questions online. They may also choose to get a paper copy sent by mail. The survey will take no more than 15-20 minutes. All questions will relate to COVID-19. Participants will be asked if they had COVID-19. They will be asked if family, friends, or members of their community did. They will answer questions about their vaccine status and access to health care services. Participants will also answer questions about how the pandemic affected their lives. They will be asked about their job and if finding childcare was a challenge. They will be asked about money problems and how they coped. They will be asked about sleep problems and emotional distress. Participants will get a $30 gift card after they finish the survey. ...

Начало: 17.06.2022 Край: 30.12.2026 Възраст: 23–35 г.

United States National Institute of Environmental Health Sciences (NI NCT05369611

By invitation only Phase 3

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Cancer

The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

Начало: 19.04.2022 Край: 31.12.2026 Възраст: 18–99 г. Treatment

Argentina, Australia, Belgium +28 AstraZeneca NCT05303532

By invitation only

Uncovering the Etiologies of Non-immune Hydrops Fetalis

Non-Immune Hydrops Fetalis

Non-immune hydrops fetalis (NIHF) is diagnosed on prenatal ultrasound when abnormal fluid collections are seen in the fetus. NIHF carries significant risks of stillbirth, preterm birth, and postnatal morbidity and mortality, particularly when the etiology remains unknown and critical opportunities for focused care and implementation of treatments are missed. In contrast, when an etiology is found, both pre- and postnatal management are directly impacted: counseling is focused, risks to the fetus and neonate are accurately anticipated, surveillance and in utero available treatments such as intrauterine transfusions are implemented, and postnatal treatments are promptly initiated to optimize outcomes. The overarching hypothesis is that discovering the precise etiologies of NIHF will create critical opportunities to improve outcomes through earlier, targeted pre- and postnatal care. Several important steps remain in order to uncover the genetic etiologies for cases remaining unsolved and improve care for these pregnancies. The study team proposes a multicenter collaboration to discover additional genetic diseases and novel variants underlying NIHF in a prospectively enrolled, large and diverse cohort utilizing whole genome sequencing (WGS) and RNA sequencing. The team will further perform comprehensive phenotyping to: a) collect detailed postnatal phenotypes and outcomes, b) re-analyze WGS data utilizing postnatal phenotype to identify diagnoses missed when sequencing algorithms incorporated only phenotype, and c) expand the phenotypes of all genetic in utero in utero diseases the investigators identify to optimize prenatal diagnosis and yield of genomic testing during pregnancy. Such a focused and comprehensive approach to the evaluation and diagnosis of NIHF has not previously been performed, particularly in a large and diverse cohort, and it is expected that this work will significantly improve the ability to understand and reshape the perinatal care for NIHF. This work will lay the foundation for redefining the approach to prenatal diagnosis, management, in utero and postnatal care for NIHF, and will create future opportunities to develop novel diagnostic algorithms and approaches to manage the complications of specific diseases underlying in utero NIHF.

Начало: 01.03.2022 Край: 28.02.2027 Възраст: 18–60 г.

United States University of California, San Francisco NCT05528796

By invitation only Phase 3

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Stereotypical Prolonged Seizures

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

Начало: 03.02.2022 Край: 30.11.2028 Възраст: от 12 г. Treatment

Australia, Bulgaria, China +9 UCB Biopharma SRL NCT05076617

By invitation only

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

Breast Cancer Ovarian Cancer Uterine Cancer

Background: A person s blood, tissue, and other samples contain DNA. Cancer is a disease of cells that are not working properly. It is caused by changes in DNA that build up. Researchers want to do future studies on DNA changes This may help them learn how to guide treatment for cancer. They need biological samples like tumors, blood, and urine for these studies. Objective: To create a place to collect and store biological samples from people with gynecologic malignancies like breast cancer. Samples from certain relatives of theirs will be collected too. Eligibility: Adults ages 18 and older who are being seen at NIH for breast cancer or other gynecologic malignancy Their biological relatives of the same age Design: Participants will answer questions about their family history. Participants will have a physical exam and medical history. This will include questions about age, ethnicity, and disease history. They will also answer questions about their medical treatments and responses. Participants will give blood and urine samples. Participants may give a tumor tissue sample. This will not be taken specifically for this study. It will be from a previous procedure or one that is already planned. Other samples may be taken only if a procedure is required for treatment. These include bone marrow, cerebrospinal fluid, and other fluids. A group of doctors and other professionals will oversee the sample storage place. The group will review all requests to be sure the use of the specimens is valid. ...

Начало: 04.01.2022 Край: 29.12.2028 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT03762733

By invitation only Phase 4

Ketamine Infusion for Neuropathic Pain in Brachial Plexus Injuries

Brachial Plexus Injury

The purpose of this study is to assess pre- and postoperative neuropathic pain in patients with traumatic brachial plexus injuries to determine if intraoperative ketamine infusion affect neuropathic pain associated with avulsion injuries of the brachial plexus.

Начало: 15.12.2021 Край: 01.12.2026 Възраст: от 18 г.

United States Mayo Clinic NCT04933149

By invitation only

Economic and Clinical Outcomes of (Whole Exome) Sequencing in Tapestry

Health Care Utilization

The purpose of this research is to learn more about the impact of genetic testing on healthcare costs, clinical care, and quality of life.

Начало: 29.10.2021 Край: 31.07.2031 Възраст: от 18 г.

United States Mayo Clinic NCT05045222

By invitation only

Wireless Nerve Stimulation Device To Enhance Recovery After Stroke

Stroke Chronic Stroke Upper Extremity Paresis Ischemic Stroke +1

Texas Biomedical Device Center (TxBDC) has developed an innovative strategy to enhance recovery of motor and sensory function after neurological injury termed targeted plasticity therapy (TPT). This technique uses brief pulses of vagus nerve stimulation to engage pro-plasticity neuromodulatory circuits during rehabilitation exercises. Preclinical findings demonstrate that VNS paired with rehabilitative training enhances recovery in multiple models of neurological injury, including stroke, spinal cord injury, intracerebral hemorrhage, and traumatic brain injury. Recovery is associated with neural plasticity in spared motor networks in the brain and spinal cord. Moreover, two initial studies and a recently completed Phase 3 clinical trial using a commercially available device demonstrates that paired VNS with rehabilitation is safe and improves motor recovery after stroke. The purpose of this study is to extend these findings and evaluate whether VNS delivered with the new device paired with rehabilitation represents a safe and feasible strategy to improve recovery of motor and sensory function in participants with stroke.

Начало: 01.09.2021 Край: 25.02.2027 Възраст: 22–79 г.

United States Baylor Research Institute NCT04534556

By invitation only Phase 3

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Начало: 27.07.2021 Край: 07.08.2030 Възраст: от 16 г.

Argentina, Belgium, Bulgaria +20 UCB Biopharma SRL NCT04976322

By invitation only

Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases

Gastrointestinal Disease

This study will be a retrospective, registry study collecting data of patients who were diagnosed with benign or malignant gastrointestinal diseases. Data will be collected from patient's chart retrospectively once the patients have completed proper treatment follow up with physicians' practice.

Начало: 07.01.2021 Край: 17.05.2030 Възраст: от 18 г.

United States Methodist Health System NCT05115877

By invitation only Phase 3

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

Mucopolysaccharidosis IIIA MPS IIIA Sanfilippo Syndrome Sanfilippo A

The main objective of this study is to evaluate the safety/tolerability and efficacy of UX111 (previously known as ABO-102) in participants with Mucopolysaccharidosis IIIA (MPS IIIA).

Начало: 28.09.2020 Край: 01.08.2027 Other

Australia, Spain, United States Ultragenyx Pharmaceutical Inc NCT04360265

By invitation only

Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors

Wide Spectrum of Diseases Hematologic Diseases

Background: Researchers seek ways to study people s medical problems in order to teach and further general knowledge. The ability to assess and treat people with a wide range of diseases is critical to training people to be good doctors. It is also needed to keep medical staff up to date. In this study, researchers want to study the course of some illnesses to learn more about them. To do this, they will collect and review people s medical records. In some cases, they may also provide treatment. Objective: To collect data that may be used to help researchers create ideas for future research. Eligibility: People age 2 and older who have or are suspected to have a medical condition for which they have been referred to NIH s National Heart, Lung, and Blood Institute, as well as stem cell donors Design: Participants may be screened with a review of the following: Medical records Scans and images Other existing samples and reports. Participants medical data will be collected from the standard care they receive. This includes their routine blood and urine tests, X-rays and scans, and other tests to diagnose or follow their medical condition. Data will also be collected from the treatments they may receive. For stem cell donors, data from apheresis procedures will be collected. Demographic data will also be collected. All of the data will be kept in the medical records or on secure network drives. Some participants may need to be treated for their medical condition. If so, they will sign a separate consent form for that treatment. Participation lasts up to 2 years.

Начало: 16.06.2020 Край: 31.12.2040 Възраст: 2–120 г.

United States National Heart, Lung, and Blood Institute (NHLBI) NCT04450927

By invitation only Phase 3

Antibiotic Prophylaxis in Rhinoplasty

Nasal Obstruction Nasal Surgical Procedures

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

Начало: 20.05.2020 Край: 20.04.2027 Възраст: от 18 г.

United States Stanford University NCT04194216

1 … 6 7 8 9 10 … 240